Amryt Pharma PLC Company Profile (LON:FAST)

About Amryt Pharma PLC (LON:FAST)

Amryt Pharma PLC logoAmryt Pharma plc, formerly Fastnet Equity plc, is a United Kingdom-based specialty pharmaceutical company. The Company focuses on developing and delivering treatments for patients with rare and orphan diseases. The Company's products include Episalvan and Imlan. The Company's products focus on developing somatostatin analogue (SSA) peptide medicines for patients with rare neuroendocrine diseases, including acromegaly and Cushing's disease. The Company's Episalvan is a prescription pharmaceutical product, which accelerates wound healing. The Company's Episalvan consists of two ingredients, such as betulin-based active ingredient and sunflower oil as the excipient. The Company's Imlan products have regenerative and anti-inflammatory properties. Betulin is the active ingredient in the Imlan products and functions as the stabilizer of the creams and lotions. The Company's Imlan Creme Pur consists of Betulin, oil and water ingredients.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: LON:FAST
  • CUSIP: N/A
  • Web: N/A
Average Prices:
  • 50 Day Moving Avg: GBX 2.91
  • 200 Day Moving Avg: GBX 2.54
  • 52 Week Range: GBX 1.85 - GBX 3.90
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
Misc:
  • Average Volume: 939,809 shs.
 

Frequently Asked Questions for Amryt Pharma PLC (LON:FAST)

What is Amryt Pharma PLC's stock symbol?

Amryt Pharma PLC trades on the London Stock Exchange (LON) under the ticker symbol "FAST."

Where is Amryt Pharma PLC's stock going? Where will Amryt Pharma PLC's stock price be in 2017?

2 brokerages have issued twelve-month price targets for Amryt Pharma PLC's shares. Their forecasts range from GBX 60 to GBX 62. On average, they expect Amryt Pharma PLC's stock price to reach GBX 61 in the next year. View Analyst Ratings for Amryt Pharma PLC.

Who are some of Amryt Pharma PLC's key competitors?

Who are Amryt Pharma PLC's key executives?

Amryt Pharma PLC's management team includes the folowing people:

  • Joe Wiley, Chief Executive Officer, Executive Director
  • , Rory Nealon, Chief Financial Officer, Chief Operating Officer, Executive Director, Company Secretary, Harry Thomas Stratford, Independent Non-Executive Chairman of the Board, James Culverwell, Senior Non-Executive Independent Director, Ray Stafford, Non-Executive Independent Director, Markus Ziener, Non-Executive Independent Director,

How do I buy Amryt Pharma PLC stock?

Shares of Amryt Pharma PLC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Amryt Pharma PLC's stock price today?

One share of Amryt Pharma PLC stock can currently be purchased for approximately GBX 2.97.


MarketBeat Community Rating for Amryt Pharma PLC (LON FAST)
Community Ranking:  2.3 out of 5 ( )
Outperform Votes:  42 (Vote Outperform)
Underperform Votes:  50 (Vote Underperform)
Total Votes:  92
MarketBeat's community ratings are surveys of what our community members think about Amryt Pharma PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Amryt Pharma PLC (LON:FAST) (?)
Ratings Breakdown: 1 Hold Rating, 1 Buy Rating
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: GBX 61

Analysts' Ratings History for Amryt Pharma PLC (LON:FAST)
Show:
DateFirmActionRatingPrice TargetDetails
5/29/2017Beaufort SecuritiesReiterated RatingSpeculative BuyGBX 62View Rating Details
4/24/2017Stifel NicolausReiterated RatingBuyGBX 60View Rating Details
(Data available from 5/29/2015 forward)

Earnings

Earnings History for Amryt Pharma PLC (LON:FAST)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Amryt Pharma PLC (LON:FAST)
Current Year EPS Consensus Estimate: $-0.33 EPS

Dividends

Dividend History for Amryt Pharma PLC (LON:FAST)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Amryt Pharma PLC (LON:FAST)
Insider Trades by Quarter for Amryt Pharma PLC (LON:FAST)
Insider Trades by Quarter for Amryt Pharma PLC (LON:FAST)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/3/2015Friel,CathalInsiderBuy3,555,394GBX 4£142,215.76
6/26/2015Friel,CathalInsiderBuy17,308,080GBX 0.04£6,923.23
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Amryt Pharma PLC (LON:FAST)
Latest Headlines for Amryt Pharma PLC (LON:FAST)
Source:
DateHeadline
americanbankingnews.com logoBeaufort Securities Reaffirms "Speculative Buy" Rating for Amryt Pharma PLC (FAST)
www.americanbankingnews.com - May 29 at 6:08 AM
americanbankingnews.com logoBeaufort Securities Reiterates Speculative Buy Rating for Amryt Pharma PLC (FAST)
www.americanbankingnews.com - May 23 at 6:18 AM
americanbankingnews.com logoAmryt Pharma PLC (FAST) Stock Rating Reaffirmed by Stifel Nicolaus
www.americanbankingnews.com - April 28 at 6:34 AM
americanbankingnews.com logoAmryt Pharma PLC (FAST) Receives Buy Rating from Stifel Nicolaus
www.americanbankingnews.com - April 24 at 1:20 PM
morningstar.co.uk logoDIRECTOR DEALINGS: Amryt Pharma Non-Exec Buys 100,000 Shares
www.morningstar.co.uk - April 10 at 4:53 PM
americanbankingnews.com logoAmryt Pharma PLC (FAST) Rating Reiterated by Beaufort Securities
www.americanbankingnews.com - April 9 at 9:19 AM
americanbankingnews.com logoAmryt Pharma PLC (FAST) Receives "Speculative Buy" Rating from Beaufort Securities
www.americanbankingnews.com - March 28 at 6:21 AM
morningstar.co.uk logoAmryt Pharma Appoints David Allmond As Chief Commercial Officer
www.morningstar.co.uk - March 27 at 11:48 AM
americanbankingnews.com logoAmryt Pharma PLC (AMYT) Rating Reiterated by Beaufort Securities
www.americanbankingnews.com - March 12 at 12:16 AM
morningstar.co.uk logoAmryt Pharma Gets Go-Ahead For Phase 3 Trial Of Skin Disorder Drug
www.morningstar.co.uk - March 6 at 4:51 PM
prnewswire.com logoAllergan to Host Third Quarter 2016 Earnings Conference Call and Webcast
www.prnewswire.com - October 13 at 4:57 PM
investorplace.com logoDump Horizon Pharma PLC (HZNP) Stock Now! Don’t Wait!
investorplace.com - October 11 at 5:08 PM
morningstar.co.uk logoAmryt Has "Transformational" First Half As Lead Drug Gets US Patent
www.morningstar.co.uk - September 13 at 9:50 AM
bloomberg.com logoMerck, Pfizer Double Size of Diabetes Drug Study to Catch Rivals
www.bloomberg.com - June 11 at 10:23 PM
morningstar.co.uk logoAmryt Pharma Plans Trials Of Episalvan Product By End Of 2016
www.morningstar.co.uk - June 9 at 7:59 AM
biz.yahoo.com logoHalf Year 2016 Fastnet Equity PLC Earnings Release - Time Not Supplied
biz.yahoo.com - December 21 at 7:07 AM

Social

Social activity is not available for this stock.

Chart

Amryt Pharma PLC (FAST) Chart for Monday, May, 29, 2017

This page was last updated on 5/29/2017 by MarketBeat.com Staff